explore -WSS

explore

author：leisure time 2025-09-06 04:13:44 - browse：3311

A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024 — Cytokinetics CEO Robert Blum spoke Thursday at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

As Cytokinetics faces pressure to sell itself to a large pharma company following positive late-stage results of its heart drug, CEO Robert Blum maintains that the biotech can launch the treatment — what would be its first approved medication — on its own.

Cytokinetics reported top-line results of its drug, aficamten, in obstructive hypertrophic cardiomyopathy, or oHCM, last December, sending its shares up on speculation the company would get acquired. Full Phase 3 results released this week further suggest the drug could be used more flexibly than a similar treatment sold by Bristol Myers Squibb, but investors have questioned whether the biotech has the resources and salesforce to compete with a large pharma company.

Blum, speaking Thursday at a talk during STAT’s Breakthrough Summit West, said that if prospective buyers approach the company, he will talk to them, but “at the same time, we’re pushing forward, as we always have, with the original intention to build a commercial business. And that’s not something new. That’s not something that’s a result of a failed M&A dialogue.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： New definition of a human embryo proposed amid rapid advances

WSS

FDA approves first treatment for ultra

Flagship Pioneering launches a new biotech in two countries

Mayo Clinic plans $5B tech

Listen: Racing for gene therapy & a pioneering approval

Diagnostic tests are hitting their mathematical limits

As Maui death toll rises, number of missing remains unclear

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Medicare details structure of new drug price negotiation program

Fetal surgery at risk from Dobbs and new abortion restrictions

BioMarin wins approval for gene therapy to treat hemophilia A

FDA approves first treatment for ultra

ChatGPT in medicine: STAT answers readers' burning questions

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Affirmative action in medical school literally saved lives

ReNAgade cuts staff seven months after raising $300 million

New air purifier tech could be key to improving indoor air quality

What to do when lifesaving products contribute to climate change

hotspot

The boys, now 6, who are gene therapy’s ‘edge case’ problem

BIO selects John Crowley as new CEO

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

Special counsel raises new conflict of interest concerns for De Oliveira's lawyer

UnitedHealth’s Optum accused of antitrust violations in California

Takeda, Janssen join wearable maker to measure scratching

focus

hotspot

Wikipedia

focus